EHA Update 2017 New Data on the Benefits of Novartis Ruxolitinib (Jakavi®) in Polycythemia vera and Myelofibrosis

被引：0
|
作者：
不详
机构：
来源：
TRANSFUSION MEDICINE AND HEMOTHERAPY | 2017年 / 44卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：372 / 372
页数：1
相关论文
共 50 条
  • [31] Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management
    Tefferi, Ayalew
    Barbui, Tiziano
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (01) : 95 - 108
  • [32] Ruxolitinib In The Treatment Of Polycythemia Vera: An Update On Health-Related Quality Of Life And Patient-Reported Outcomes
    Cingam, Shashank
    Flatow-Trujillo, Lainey
    Andritsos, Leslie A.
    Yi, Cecilia Arana
    JOURNAL OF BLOOD MEDICINE, 2019, 10 : 381 - 390
  • [33] A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
    Mascarenhas, J.
    Marcellino, B. K.
    Lu, M.
    Kremyanskaya, M.
    Fabris, F.
    Sandy, L.
    Mehrotra, M.
    Houldsworth, J.
    Najfeld, V.
    El Jamal, S.
    Petersen, B.
    Moshier, E.
    Hoffman, R.
    LEUKEMIA RESEARCH, 2020, 88
  • [34] Miliary TB and COVID-19 Coinfection in a Patient With a History of Post-polycythemia Vera Myelofibrosis Treated With Ruxolitinib: A Case Report
    Loutsou, Maria
    Georgakopoulou, Vasiliki E.
    Roussakis, Nikolaos
    Chadia, Konstantina
    Steiropoulos, Paschalis
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [35] The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
    Ikeda, Kazuhiko
    Ueda, Koki
    Sano, Takahiro
    Ogawa, Kazuei
    Ikezoe, Takayuki
    Hashimoto, Yuko
    Morishita, Soji
    Komatsu, Norio
    Ohto, Hitoshi
    Takeishi, Yasuchika
    INTERNAL MEDICINE, 2017, 56 (13) : 1705 - 1710
  • [36] A RUXOLITINIB INDIVIDUAL SUPPLY PROGRAM FOR PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
    Barosi, G.
    Linardi, C.
    Ben Yehuda, D.
    Henrique Daumas Gabriel, A.
    Perez, J.
    Modi, A.
    Khan, M.
    Zweegman, S.
    Raymakers, R.
    Vianelli, N.
    Pakstyte, S.
    Willenbacher, W.
    Gisslinger, H.
    HAEMATOLOGICA, 2012, 97 : 321 - 321
  • [37] RUXOLITINIB PLUS PANOBINOSTAT IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: A PHASE 1B DOSE-FINDING STUDY
    Vannucchi, A. M.
    Heidel, F. H.
    Ribrag, V.
    Kiladjian, J. J.
    Passamonti, F.
    Hayat, A.
    Conneally, E.
    Kindler, T.
    Martino, B.
    Lipka, D. B.
    Acharyya, S.
    Gopalakrishna, P.
    Loechner, S.
    Mu, S.
    Harrison, C. N.
    HAEMATOLOGICA, 2014, 99 : 129 - 130
  • [38] COMPASSIONATE USE PROGRAM (CUP) WITH RUXOLITINIB IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
    Vargas, P.
    Karpovitch, X.
    Alvarado, M.
    Ovilla, R.
    Agreda, G.
    Guzman, P.
    Solis, J.
    Kassack, J.
    Silva, S.
    Zavala, S.
    Morales, J.
    Herrera, A.
    Reynoso, E.
    Rodriguez, M.
    Ruiz, G.
    Sobrevilla, P.
    Garcia, M.
    Aguilar, C.
    Morales, R.
    Barrera, E.
    Osuna, A.
    Carrillo, R.
    Silos, G.
    Vega, A.
    Cuin, S.
    Mora, M.
    Best, C.
    Murillo, E.
    Loarca, L.
    Perez, O.
    Salazar, J.
    Baez, E.
    Montemayor, J.
    Barrera, D.
    Garcia, J.
    Peraza, L.
    Baltazar, S.
    Iniguez, L.
    Oseguera, R.
    Nacho, K.
    Romero, T.
    HAEMATOLOGICA, 2013, 98 : 765 - 766
  • [39] THE ROLE OF ALPHA-INTERFERON IN ESSENTIAL THROMBOCYTHEMIA, POLYCYTHEMIA-VERA AND MYELOFIBROSIS WITH MYELOID METAPLASIA (MMM) - A CONCISE UPDATE
    SACCHI, S
    LEUKEMIA & LYMPHOMA, 1995, 19 (1-2) : 13 - 20
  • [40] REVIEU-Study Real-Life-Data for the Treatment of chronic ITP with Novartis' Revolade® is presented at the EHA 2017
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2017, 44 (05) : 372 - 372
12345